About: Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic n

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic n Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by N Hotta et al published December 2012 in Diabetic Medicine

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2012 (fr) наукова стаття, опублікована в грудні 2012 (uk) im Dezember 2012 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by N Hotta et al published December 2012 in Diabetic Medicine (en)
publication date	wds:Q59925982-64084EE9-949B-407C-8A9C-3AB0FFFD0FF4
publication date	2012-12-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q59925982-36839EFA-CD6C-46F9-9DE8-A36EF24CE491
language of work or name	English
cites work	wds:Q59925982-03ED0521-6559-447A-8AC2-7A0B3B24C0E9 wds:Q59925982-097BC93E-15D2-456E-8378-BDF6C51E0E11 wds:Q59925982-0C171E16-FAE7-4A24-9685-5A72C1B647C5 wds:Q59925982-1730AA92-51C7-4D1A-BB4F-B76F906692A2 wds:Q59925982-2A69F06B-3113-450A-AEF2-4D742DAF2703 wds:Q59925982-352DBBB2-5BD0-4145-99CD-7A17AC5CA070 wds:Q59925982-38A4F292-2653-4AAD-B703-79D757265B47 wds:Q59925982-3CD7766B-5C5A-48DC-836E-4931B9418983 wds:Q59925982-53248898-A3A8-4B28-BF4C-A51B0996E7C6 wds:Q59925982-632E08AE-3156-4D13-AB5E-BD5B2D7529B3 wds:Q59925982-66F097B7-AA05-4633-A9A0-B70F1AEA7710 wds:Q59925982-6C6F66CA-5E6F-486D-9CC8-C2C0DDD1E97B wds:Q59925982-7CDD4D95-9215-4560-AFF0-E0ABDFEB0270 wds:Q59925982-82ECB23F-9592-4FCE-974E-7AC399228AA1 wds:Q59925982-84164F3F-EFAD-4763-9D00-F8AF917AE36A wds:Q59925982-8D297C94-B74C-4423-AA94-CF4B7E348C40 wds:Q59925982-8D5E1E23-8F70-446C-991D-090E39AA3C68 wds:Q59925982-974AC423-06FD-4A86-87A1-05A7EFF5FB78 wds:Q59925982-A48E0EE7-6228-4BDF-87EB-803C7FAF24A9 wds:Q59925982-AD0E6441-BF80-48C1-A0CC-E64C752BEB1B wds:Q59925982-B43DEFAC-C1B7-4DE9-BA94-8D9DB59B274C wds:Q59925982-C691339F-4320-49E3-9DC7-1D035CE92C82 wds:Q59925982-CEC57A08-A595-422F-82EE-DA7E94EEC32A wds:Q59925982-D37453C5-F4D8-4459-888C-B415D73886E4 wds:Q59925982-D5B2F3D5-9456-422A-A779-46B98DDEDEB7 wds:Q59925982-D990CE09-C70A-44A1-8401-E5CBF5AD944A wds:Q59925982-E04E335F-8AC5-438D-960E-4A1CEC759E4A wds:Q59925982-E803B09E-0F46-431C-B06B-6A6B91B5E9C8 wds:Q59925982-EC9FF63B-BB7C-4286-8D1D-4A0FE246878F wds:Q59925982-F39341C9-8024-49DD-A88C-4E3408058135
cites work	Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments Vascular risk factors and diabetic neuropathy Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial Aldose reductase, still a compelling target for diabetic neuropathy Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes Is there a place for inhibition of transforming growth factor-β and the polyol pathway in therapy for diabetic retinopathy? Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study Standards of medical care in diabetes--2011. Protein kinase C activation and the development of diabetic complications Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group Recent advances in the management of diabetic distal symmetrical polyneuropathy Report of the committee on the classification and diagnostic criteria of diabetes mellitus The sorbitol pathway and the complications of diabetes Diabetic nephropathy Mechanism of diabetic neuropathy: Where are we now and where to go? Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: the EURODIAB Prospective Complications Study Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden Is peripheral neuropathy associated with retinopathy and albuminuria in individuals with impaired glucose metabolism? The 1999-2000 AusDiab The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy The role of protein kinase C activation in diabetic nephropathy Current and future strategies for the management of diabetic neuropathy Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review PKC inhibition and diabetic microvascular complications Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat The value of skin biopsy with recording of intraepidermal nerve fiber density and quantitative sensory testing in the assessment of small fiber involvement in patients with different causes of polyneuropathy
author name string	wds:Q59925982-181BB425-4145-4A09-8B61-566C2013994B wds:Q59925982-50704226-ED2C-4A96-9ECC-3E89571C5483 wds:Q59925982-5A06F4E5-CE3B-48C0-A7FC-DEC1475F18BE wds:Q59925982-B56F055B-F028-4587-B5FC-6A9CE3CFA6BA
author name string	M Fukuda Y Shigeta N Hotta R Kawamori
rdfs:label	Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic n (en) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic n (nl)
skos:prefLabel	Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic n (en) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic n (nl)
name	Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic n (en) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic n (nl)
title	wds:Q59925982-EA036263-09E6-4D1D-BA73-8C3A9B386983
title	Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic n (en)
page(s)	wds:Q59925982-8E315785-DFD5-4C39-A62C-06BFD5EF7278
page(s)	1529-33
instance of	wds:Q59925982-D10A125B-9756-4366-BA61-4CDCE914A454
instance of	scholarly article
main subject	wds:Q59925982-5B9C349C-7976-4F1A-8B36-1B2C499C769A wds:Q59925982-A52FF604-BBE6-471F-9C46-C97C1C3D736D wds:Q59925982-ADF40E2B-DAC2-4020-B899-CD7C4A031CAA
main subject	epidemiology diabetic neuropathy multivariate statistics
PubMed ID	wds:Q59925982-3FCEC5C1-19D4-4668-9347-BBA3D665F52D
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22507139
PubMed ID	22507139
published in	wds:Q59925982-D70AB60E-C8E2-4CD2-B606-2D59B91DDA0A

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software